Literature DB >> 27036867

Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats.

C M Happé1, M A de Raaf1, N Rol1, I Schalij1, A Vonk-Noordegraaf2, N Westerhof3, N F Voelkel4, F S de Man2, H J Bogaard5.   

Abstract

The SU5416 + hypoxia (SuHx) rat model is a commonly used model of severe pulmonary arterial hypertension. While it is known that exposure to hypoxia can be replaced by another type of hit (e.g., ovalbumin sensitization) it is unknown whether abnormal pulmonary blood flow (PBF), which has long been known to invoke pathological changes in the pulmonary vasculature, can replace the hypoxic exposure. Here we studied if a combination of SU5416 administration combined with pneumonectomy (PNx), to induce abnormal PBF in the contralateral lung, is sufficient to induce severe pulmonary arterial hypertension (PAH) in rats. Sprague Dawley rats were subjected to SuPNx protocol (SU5416 + combined with left pneumonectomy) or standard SuHx protocol, and comparisons between models were made at week 2 and 6 postinitiation. Both SuHx and SuPNx models displayed extensive obliterative vascular remodeling leading to an increased right ventricular systolic pressure at week 6 Similar inflammatory response in the lung vasculature of both models was observed alongside increased endothelial cell proliferation and apoptosis. This study describes the SuPNx model, which features severe PAH at 6 wk and could serve as an alternative to the SuHx model. Our study, together with previous studies on experimental models of pulmonary hypertension, shows that the typical histopathological findings of PAH, including obliterative lesions, inflammation, increased cell turnover, and ongoing apoptosis, represent a final common pathway of a disease that can evolve as a consequence of a variety of insults to the lung vasculature.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  SU5416; flow; hypoxia; pneumonectomy; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27036867     DOI: 10.1152/ajplung.00023.2016

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  13 in total

1.  CrossTalk proposal: The mouse SuHx model is a good model of pulmonary arterial hypertension.

Authors:  Krishna C Penumatsa; Rod R Warburton; Nicholas S Hill; Barry L Fanburg
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

2.  Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension.

Authors:  Diederik E van der Feen; Michel Weij; Annemieke Smit-van Oosten; Lysanne M Jorna; Quint A J Hagdorn; Beatrijs Bartelds; Rolf M F Berger
Journal:  J Vis Exp       Date:  2017-02-11       Impact factor: 1.355

3.  Vascular remodelling in the pulmonary circulation after major lung resection.

Authors:  Nina Rol; Chris Happé; Jeroen A M Beliën; Frances S de Man; Nico Westerhof; Anton Vonk-Noordegraaf; Katrien Grünberg; Harm J Bogaard
Journal:  Eur Respir J       Date:  2017-08-31       Impact factor: 16.671

4.  The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats.

Authors:  Michael G Katz; Anthony S Fargnoli; Sarah M Gubara; Malik Bisserier; Yassine Sassi; Charles R Bridges; Roger J Hajjar; Lahouaria Hadri
Journal:  J Vis Exp       Date:  2019-03-08       Impact factor: 1.355

5.  Right predominant electrical remodeling in a pure model of pulmonary hypertension promotes reentrant arrhythmias.

Authors:  Benjamin Strauss; Malik Bisserier; Emerson Obus; Michael G Katz; Anthony Fargnoli; Marine Cacheux; Joseph G Akar; James P Hummel; Lahouaria Hadri; Yassine Sassi; Fadi G Akar
Journal:  Heart Rhythm       Date:  2021-09-23       Impact factor: 6.779

Review 6.  From Here to There, Progenitor Cells and Stem Cells Are Everywhere in Lung Vascular Remodeling.

Authors:  Rebecca L Heise; Patrick A Link; Laszlo Farkas
Journal:  Front Pediatr       Date:  2016-08-17       Impact factor: 3.418

7.  Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease.

Authors:  Florence Coste; Christelle Guibert; Julie Magat; Emma Abell; Fanny Vaillant; Mathilde Dubois; Arnaud Courtois; Philippe Diolez; Bruno Quesson; Roger Marthan; Jean-Pierre Savineau; Bernard Muller; Véronique Freund-Michel
Journal:  Respir Res       Date:  2017-03-14

8.  BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).

Authors:  Andrea Frump; Allison Prewitt; Mark P de Caestecker
Journal:  Pulm Circ       Date:  2018-03-09       Impact factor: 3.017

9.  Toward Better Reproducibility in Experimental Research on New Agents for Pulmonary Hypertension. An Analysis of Data from Four Hundred Animal Studies.

Authors:  Magdalena Jasińska-Stroschein
Journal:  Cardiovasc Drugs Ther       Date:  2020-12-09       Impact factor: 3.727

10.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.